Q2 saw 5% sales growth and strong cash generation, led by specialty medicines and vaccines. The Accelerate Growth program targets £1.9B in annual savings to fund R&D and protect margins through key LOE periods, while the Nuvalent acquisition expands the oncology pipeline.Based on GSK plc [GSK] Q2 2…
GSK, a global pharmaceutical and vaccine manufacturer, rose 1% in Tuesday's London trading after climbing as much as 5% following stronger-than-expected second-quarter results. The company announced a 1.9 billion, or approximately $2.52 billion, cost-savings program designed primarily to fund addit…
Q2 saw 5% sales growth and strong momentum in Specialty medicines and Vaccines, with updated 2026 guidance reflecting higher sales and operating profit expectations. The Accelerate Growth program will fund R&D and late-stage pipeline expansion, supported by robust cash flow and disciplined capital…
Q2 2026 saw 5% sales growth to £8.4bn, with core operating profit up 7% and EPS up 9%. Specialty Medicines and Vaccines drove performance, while the Accelerate Growth programme is reallocating capital to late-stage R&D. Guidance for 2026 remains at the upper end for sales and profit.Original docume…
Q2 2026 saw strong core sales and profit growth, led by Specialty Medicines and Vaccines, while total profit and EPS declined due to significant impairments. Guidance for 2026 is reaffirmed, with robust R&D acceleration, major restructuring, and continued shareholder returns through dividends and b…
GSK (LSE:GSK) won FDA approval for Jideytro to treat ROS1+ advanced NSCLC after prior ROS1 inhibitors, citing strong ARROS‑1 responses including brain mets and resistance mutations, even as mixed late‑stage cough data halted camlipixant trials and the company readies Q2 results.Previous Week Recap…
LONDON, July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer…
GSK NYSE:GSK, a British drugmaker, has stopped developing camlipixant after concluding that the experimental treatment for refractory chronic cough was unlikely to transform patient care. The decision followed mixed late-stage results, with a high dose reducing cough frequency in one study but fail…
GSK shares fell ~2% after negative late‑stage trial results for chronic cough drug camlipixant. Citi called the asset high‑risk with ~25% success odds; analysts had modeled 2035 sa
RNS Number : 9778M GSK PLC 20 July 2026 Issued: 20 July 2026, London UKEuropean Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds· If approved, a single booster dose could help protect individuals who were previously vaccinated with B…
RNS Number : 6852M GSK PLC 16 July 2026 GSK plc (the 'Company')Transaction notificationAbout GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.Registered in England & Wales:No. 3888792Regis…
RNS Number : 5058M GSK PLC 15 July 2026 Issued: 15 July 2026, London UKGSK completes acquisition of Nuvalent, Inc.GSK plc (LSE/NYSE: GSK) today announced completion of its acquisition of Nuvalent, Inc.[1], a Boston-based clinical-stage biopharmaceutical company focused on creating precisely tar…
RNS Number : 3279M GSK PLC 14 July 2026 GSK plc (the 'Company')Transaction notificationAbout GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.Registered in England & Wales:No. 3888792Regis…
RNS Number : 9745L GSK PLC 13 July 2026 Issued: 13 July 2026, London UKJemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer· Primary objective met in interim analysis, with clinically significant rate of participants showing no det…
RNS Number : 9284L GSK PLC 10 July 2026 Issued: 10 July 2026, London UKGSK's licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population· ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or rel…
By Tharuniyaa LakshmiLondon's FTSE 100 ended lower on Monday as losses in precious metal miners and drugmakers including AstraZeneca weighed, while easyJet topped the midcap index after agreeing to a takeover offer.The blue-chip FTSE 100 index CURRENCYCOM:UK100 fell 0.3% to 10,651.8 points at close…
